Sort   by:  
 Page size 
MetabolomicsUntargeted Plasma Lipidomics Identifies Oxidative Stress and Inflammation Signatures Associated with Recurrent Leg Ulcer Status in Sickle Cell Disease

Leg ulcers are among the most burdensome complications of sickle cell disease (SCD), yet the molecular determinants underlying ulcer susceptibility and recurrence remain incompletely characterized. We performed untargeted plasma lipidomics by LC–MS in 129 individuals with SCD from the REDS-III Br...

2025-12-19 | MTBLS13538 | MetaboLights
MetabolomicsPCOS preterm plasma metabolome

This study investigated mid-trimester plasma metabolomic profiles in pregnant women to identify biomarkers associated with Polycystic Ovary Syndrome (PCOS) and preterm birth. A total of 149 participants were categorized into four groups: 32 with PCOS and preterm delivery, 34 with PCOS and term de...

2025-09-09 | MTBLS12968 | MetaboLights
MetabolomicsLC-MS metabolic profiling of mouse plasma and cell culture medium in relation to ABCC6 expression
Pseudoxanthoma elasticum (PXE) is an autosomal recessive disease characterized by progressive ectopic mineralization of the skin, eyes and arteries, for which no effective treatment exists. PXE is caused by inactivating mutations in the gene encoding ABCC6 (MRP6), an ATP-dependent efflux transporter...
2013-11-14 | MTBLS61 | MetaboLights
MetabolomicsPregnancy-Induced Metabolic Phenotype Variations in Maternal Plasma
Metabolic variations occur during normal pregnancy to provide the growing fetus with a supply of nutrients required for its development and to ensure the health of the woman during gestation. Mass spectrometry-based metabolomics was employed to study the metabolic phenotype variations in the materna...
2015-03-03 | MTBLS146 | MetaboLights
MetabolomicsPostoperative Metabolic Phenoreversion in Clear Cell Renal Cell Carcinoma

The ultimate goal of surgical treatment in cancer is to remove the tumor mass for restoring a healthy state. A 16-lipid panel that discriminated healthy controls from clear cell renal cell carcinoma (ccRCC) patients in a prior study was evaluated in the present work in paired-serum samples collec...

2023-01-02 | MTBLS3838 | MetaboLights
MetabolomicsImpact of myocardial reperfusion on human plasma lipidome
The primary aim of the study is to investigate the temporal changes in plasma lipidome before and after reperfusion in patients with ST-segment elevation myocardial infarction (STEMI) and their association with myocardial injury. We found that 56% of the identified lipid species were significantly a...
2022-02-07 | MTBLS3839 | MetaboLights
MetabolomicsUntargeted metabolomics analysis of COPD plasma

Background: Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory disorder with rising global morbidity and mortality. Emerging evidence suggests that systemic metabolic alterations, particularly dyslipidemia, contribute to COPD pathogenesis. However, the mechanisms link...

2025-11-26 | MTBLS13388 | MetaboLights
MetabolomicsAssociation between altered tryptophan metabolism, plasma aryl hydrocarbon receptor agonists, and inflammatory Chagas disease

Chagas disease causes a cardiac illness characterized by immunoinflammatory reactions leading to myocardial fibrosis and remodeling. The development of Chronic Chagas Cardiomyopathy (CCC) in some patients while others remain asymptomatic is not fully understood, but dysregulated inflammatory resp...

2024-01-11 | MTBLS8390 | MetaboLights
MetabolomicsA polyamine-centric blood-based metabolite panel predictive of poor response to CAR T-cell therapy in large B cell lymphoma

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (r/r) large B-cell lymphoma (LBCL) results in durable response in only a subset of patients. MYC overexpression in LBCL tumors is associated with poor response to treatment. We tested whether a MYC-driven polyamin...

2022-10-31 | MTBLS5381 | MetaboLights
MetabolomicsPlasma Lipidomics Identifies Anticedent Memory Impairment in Older Adults
Alzheimer's disease causes a progressive dementia that currently affects over 35 million individuals worldwide and is expected to affect 115 million by 2050 (ref. 1). There are no cures or disease-modifying therapies, and this may be due to our inability to detect the disease before it has progresse...
2014-03-09 | MTBLS72 | MetaboLights
Sort   by:  
 Page size